Difference between revisions of "Trimethoprim-Sulfamethoxazole (Bactrim DS)"
(Created page with "==General information== Class/mechanism: <ref name="insert">[http://www.accessdata.fda.gov/drugsatfda_docs/label/2003/17377slr057_Bactrim_lbl.pdf Trimethoprim/Sulfamethoxazole (B...") |
|||
| Line 1: | Line 1: | ||
==General information== | ==General information== | ||
| − | Class/mechanism: <ref name="insert">[http://www.accessdata.fda.gov/drugsatfda_docs/label/2003/17377slr057_Bactrim_lbl.pdf Trimethoprim/Sulfamethoxazole (Bactrim DS) package insert]</ref><ref>[http://hemonc.org/docs/packageinsert/trimethoprim/sulfamethoxazole.pdf Trimethoprim/Sulfamethoxazole (Bactrim DS) package insert (locally hosted backup)]</ref> | + | Class/mechanism: Sulfonamide antibiotic, combination of trimethoprim and sulfamethoxazole. Sulfamethoxazole and trimethoprim work synergistically to block two consecutive steps of nucleic acid synthesis in bacteria. Sulfamethoxazole is a competitive inhibitor of para-aminobenzoic acid (PABA) and blocks bacterial synthesis of dihydrofolic acid. Trimethoprim reversibly inhibits dihydrofolate reductase, blocking the production of tetrahydrofolic acid from dihydrofolic acid.<ref name="insert">[http://www.accessdata.fda.gov/drugsatfda_docs/label/2003/17377slr057_Bactrim_lbl.pdf Trimethoprim/Sulfamethoxazole (Bactrim DS) package insert]</ref><ref>[http://hemonc.org/docs/packageinsert/trimethoprim/sulfamethoxazole.pdf Trimethoprim/Sulfamethoxazole (Bactrim DS) package insert (locally hosted backup)]</ref> |
| − | <br>Route: | + | <br>Route: PO, IV |
| − | <br>Extravasation: | + | <br>Extravasation: no information |
| − | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the | + | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information<ref name="insert"></ref>. |
==Patient drug information== | ==Patient drug information== | ||
| − | *[http://www.uptodate.com/contents/trimethoprim | + | *[http://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-patient-drug-information Trimethoprim/Sulfamethoxazole (Bactrim DS) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-patient-drug-information Trimethoprim/Sulfamethoxazole (Bactrim DS) patient drug information (UpToDate)]</ref> |
==References== | ==References== | ||
<references/> | <references/> | ||
Revision as of 00:51, 26 February 2012
General information
Class/mechanism: Sulfonamide antibiotic, combination of trimethoprim and sulfamethoxazole. Sulfamethoxazole and trimethoprim work synergistically to block two consecutive steps of nucleic acid synthesis in bacteria. Sulfamethoxazole is a competitive inhibitor of para-aminobenzoic acid (PABA) and blocks bacterial synthesis of dihydrofolic acid. Trimethoprim reversibly inhibits dihydrofolate reductase, blocking the production of tetrahydrofolic acid from dihydrofolic acid.[1][2]
Route: PO, IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information[1].